Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marleen Kok

Showing results (1-10 of 101) with videos related to

Pageof 11
Sort By:
Current Treatment Options in Oncology|April 20, 2023
Immunotherapy for Metastatic Triple Negative Breast Cancer: Current Paradigm and Future ApproachesVeerle Geurts, Marleen Kok
Immunity|December 13, 2023
Chi3l1: New kid on the T cell blockadeMi He, Marleen Kok
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2026
Immunity, age, and luminal breast cancer: understanding the Holy TrinityRoberto Salgado, Marleen Kok
ESMO Open|June 25, 2019
How I treat MSI cancers with advanced diseaseMarleen Kok, Myriam Chalabi, John Haanen
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2023
Facts and Hopes in Immunotherapy for Early-Stage Triple-Negative Breast CancerIris Nederlof, Leonie Voorwerk, Marleen Kok
Cancer Treatment and Research|April 5, 2011
Estrogen receptor phenotypes defined by gene expression profilingMarleen Kok, Sabine Linn, Marc van de Vijver
Current Opinion in Obstetrics & Gynecology|February 17, 2016
Targeting the programmed cell death-1 pathway in breast and ovarian cancerLeisha A Emens, Marleen Kok, Laureen S Ojalvo
Cancers|January 20, 2021
A High-Dimensional Window into the Micro-Environment of Triple Negative Breast CancerIris Nederlof, Hugo M Horlings, Christina Curtis, et al.
Oncogene|February 20, 2003
CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous systemPatricia M Thompson, Takahiro Gotoh, Marleen Kok, et al.
The EMBO Journal|October 18, 2011
Oestrogen receptor-co-factor-chromatin specificity in the transcriptional regulation of breast cancerWilbert Zwart, Vasiliki Theodorou, Marleen Kok, et al.
Pageof 11

Showing results (1-10 of 101) with videos related to

Sort By:
Pageof 11
Current Treatment Options in Oncology|April 20, 2023
Immunotherapy for Metastatic Triple Negative Breast Cancer: Current Paradigm and Future ApproachesVeerle Geurts, Marleen Kok
Immunity|December 13, 2023
Chi3l1: New kid on the T cell blockadeMi He, Marleen Kok
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2026
Immunity, age, and luminal breast cancer: understanding the Holy TrinityRoberto Salgado, Marleen Kok
ESMO Open|June 25, 2019
How I treat MSI cancers with advanced diseaseMarleen Kok, Myriam Chalabi, John Haanen
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2023
Facts and Hopes in Immunotherapy for Early-Stage Triple-Negative Breast CancerIris Nederlof, Leonie Voorwerk, Marleen Kok
Cancer Treatment and Research|April 5, 2011
Estrogen receptor phenotypes defined by gene expression profilingMarleen Kok, Sabine Linn, Marc van de Vijver
Current Opinion in Obstetrics & Gynecology|February 17, 2016
Targeting the programmed cell death-1 pathway in breast and ovarian cancerLeisha A Emens, Marleen Kok, Laureen S Ojalvo
Cancers|January 20, 2021
A High-Dimensional Window into the Micro-Environment of Triple Negative Breast CancerIris Nederlof, Hugo M Horlings, Christina Curtis, et al.
Oncogene|February 20, 2003
CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous systemPatricia M Thompson, Takahiro Gotoh, Marleen Kok, et al.
The EMBO Journal|October 18, 2011
Oestrogen receptor-co-factor-chromatin specificity in the transcriptional regulation of breast cancerWilbert Zwart, Vasiliki Theodorou, Marleen Kok, et al.
Pageof 11